Price Alert: Shares of Assembly (ASMB) Trade 6.50% Higher at Midday June 21

Equities Staff  |

Assembly Biosciences Inc (NASDAQ: ASMB) shares climbed 6.50%, or $0.13 per share, as on 11:47:05 est today. Since opening the day at $2.03, 234,483 shares of Assembly have exchanged hands and the stock has traded between $2.16 and $2.02.  

Already the company is down 14.16%.

Assembly is set to release earnings on 2022-08-04.

For technical charts, analysis, and more on Assembly visit the company profile.

About Assembly Biosciences Inc

Assembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio's approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio's strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.

To get more information on Assembly Biosciences Inc and to follow the company's latest updates, you can visit the company's profile page here: Assembly Biosciences Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content